Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
December 10, 2007, Somaxon Pharmaceuticals to Present
at RBC Capital Markets 2007 Healthcare Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today announced that Ken Cohen, president and chief executive officer, will
participate in a panel presentation at the RBC Capital Markets 2007 Healthcare Conference at
the Westin New York Hotel at Times Square in New York City on Thursday, December 13,
2007, at 10:00 a.m. ET (7:00 a.m. PT). Webcast available.
Additional details are contained in the attached press release. (.pdf)
December 6, 2007, SOMAXON PHARMACEUTICALS NAMES DAVID F. HALE
EXECUTIVE CHAIRMAN AND INTERIM CHIEF EXECUTIVE OFFICER
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a
specialty pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
said that its current non-executive Chairman of the Board, David F. Hale, has been appointed
Executive Chairman, effective immediately, and will become interim Chief Executive Officer of the company, effective January 1, 2008. Kenneth M. Cohen has resigned as President and Chief
Executive Officer of the company, effective December 31, 2007. (.pdf)
November, 7, 2007, SOMAXON PHARMACEUTICALS REPORTS 2007 THIRD QUARTER FINANCIAL RESULTS
* Third quarter 2007 net loss was $5.7 million, or $0.31 per share, vs. $9.8 million, or $0.55 per share, in the 2006 third quarter
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced financial results for the third quarter ended September 30, 2007.
Conference call scheduled today at 1:30 p.m. PT. Additional details are contained in the attached press release. (.pdf)
October 31, 2007, Somaxon Pharmaceuticals to Report 2007 Third Quarter
Financial Results and Host Conference Call
on November 7, 2007
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
today announced that it will release its 2007 third quarter financial results after the market closes
on Wednesday, November 7, 2007. Somaxon management will host a conference call that same
afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions.
Additional details are contained in the attached press release. (.pdf)
October 1, 2007, Somaxon Pharmaceuticals to Present
at the Natixis Bleichroeder Hidden Gems Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
today announced that Ken Cohen, president and chief executive officer, will present a
company overview at the Natixis Bleichroeder Hidden Gems Conference at the Carlton Hotel
on Madison Avenue in New York City on Monday, October 8, 2007, at 11:45 a.m. PT (2:45
p.m. ET). (.pdf)
September 12, 2007, Somaxon Pharmaceuticals to Present
at the Merriman Curhan Ford 4th Annual Investor Summit
and ThinkEquity Partners G5: The Growth Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today announced that Ken Cohen, president and chief executive officer, will present
at the following two upcoming investor conferences:
* Merriman Curhan Ford 4th Annual Investor Summit
Monday, September 17, 2007, at 8:00 a.m. PT (11:00 a.m. ET)
Mark Hopkins InterContinental Hotel – San Francisco, CA
* ThinkEquity Partners G5: The Growth Conference
Tuesday, September 18, 2007, at 9:30 a.m. PT (12:30 p.m. ET)
St. Regis Hotel – San Francisco, CA
Additional details are contained in the attached press release. (.pdf)
August 7, 2007, SOMAXON PHARMACEUTICALS REPORTS 2007 SECOND QUARTER FINANCIAL RESULTS
- Second quarter 2007 net loss of $6.0 million, or $0.33 per share, vs. $14.7 million, or $0.82
per share, in 2006 second quarter
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced financial results for the second quarter ended June 30, 2007. (.pdf)
July 31, 2007, Somaxon Pharmaceuticals to Report 2007 Second Quarter Financial Results and Host Conference Call
on August 7, 2007
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2007 second quarter financial results after the market closes on Tuesday, August 7, 2007. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions. (.pdf)
June 7, 2007, Somaxon Pharmaceuticals to Present
at the Needham Biotechnology & Medical Technology
Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Jeff Raser, senior vice president, sales and marketing, will present a
company update at the Needham Biotechnology & Medical Technology Conference at the
New York Palace Hotel on Thursday, June 14, 2007, at 10:00 a.m. ET (7:00 a.m. PT).
A live webcast of the presentation will be available. Additional details are contained in the attached press release. (.pdf)
June 1, 2007, SOMAXON PHARMACEUTICALS APPOINTS
MICHAEL L. EAGLE TO BOARD OF DIRECTORS
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced the appointment of Michael L. Eagle as an independent director of the company. (.pdf)
May 23, 2007, Somaxon Pharmaceuticals to Present
at Friedman, Billings, Ramsey 2007 Growth Conference
and Bank of America 2007 Health Care Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will present at the following two upcoming conferences:
* Friedman, Billings, Ramsey & Co. 2007 Growth Conference Wednesday, May 30, 2007, at 11:15 a.m. ET (8:15 a.m. PT)
* Bank of America 2007 Health Care Conference Friday, June 1, 2007, at 8:40 a.m. PT (11:40 a.m. ET)
Additional details are contained in the attached press release. (.pdf)
May 9, 2007, SOMAXON PHARMACEUTICALS PROVIDES UPDATE ON SILENOR™ DEVELOPMENT PROGRAM
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today
provided an update on its non-clinical program for SILENOR™ (doxepin HCl), its lead product
candidate that has completed a successful Phase 3 clinical program for the treatment of insomnia. (.pdf)
May 8, 2007, SOMAXON PHARMACEUTICALS REPORTS
2007 FIRST QUARTER FINANCIAL RESULTS
- First quarter 2007 net loss of $6.9 million, or $0.38 per share, vs. $13.5 million, or $0.75 per
share, in 2006 first quarter
- New Drug Application (NDA) submission for SILENOR™ (doxepin HCl) planned for third
quarter of 2007
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced financial results for the first quarter ended March 31, 2007. (.pdf)
May 1, 2007, Somaxon Pharmaceuticals to Report 2007 First Quarter Financial Results and Host Conference Call
on May 8, 2007
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
today announced that it will release its 2007 first quarter financial results before the
market opens on Tuesday, May 8, 2007. Somaxon management will host a conference
call that same morning at 8:30 a.m. ET (5:30 a.m. PT) to review the financial results and
answer questions. (.pdf)
April 19, 2007, Somaxon Pharmaceuticals to Present at Upcoming Fortis, Morgan Stanley and UBS Conferences in April and May
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will present at the following three upcoming conferences:
* Fortis 7th Annual Biotechnology Conference
Wednesday, April 25, 2007, at 4:00 p.m. GMT (11:00 a.m. ET)
* Morgan Stanley Global Healthcare Unplugged Conference
Wednesday, May 2, 2007 , at 2:15 p.m. ET ( 11:15 a.m. PT)
* UBS 2007 Global Generic and Specialty Pharmaceuticals Conference
Wednesday, May 9, 2007, at 9:00 a.m. ET (6:00 a.m. PT)
Additional details are contained in the attached press release. (.pdf)
April 3, 2007, SOMAXON PHARMACEUTICALS NAMES JAMES L’ITALIEN, PH.D.,
SENIOR VICE PRESIDENT, REGULATORY AFFAIRS AND QUALITY ASSURANCE
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today
announced the appointment of James L’Italien, Ph.D., as Senior Vice President, Regulatory Affairs
and Quality Assurance, a newly created position. (.pdf)
March 13, 2007, SOMAXON REPORTS
2006 FULL YEAR FINANCIAL RESULTS
- Full year 2006 net loss of $46.4 million, or $2.58 per share
- New Drug Application (NDA) submission for SILENOR™ (doxepin HCl) planned for third
quarter of 2007
SAN DIEGO, CA− Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced financial results for the fourth quarter and full year ended December 31, 2006. (.pdf)
March 7, 2007, Somaxon Pharmaceuticals to Present at the Cowen and Company 27th Annual Health Care Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a
company update at the Cowen and Company 27th Annual Health Care Conference at the
Boston Marriott Copley Place, on Wednesday, March 14, 2007, at 8:45 a.m. Eastern Time
(5:45 a.m. Pacific Time). (.pdf)
March 6, 2007, Somaxon Pharmaceuticals to Report 2006 Fourth Quarter
and Full-Year Financial Results and Host Conference Call on March 13, 2007
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today announced that it will release its 2006 fourth quarter and full-year
financial results before the market opens on Tuesday, March 13, 2007. Somaxon
management will host a conference call that same morning at 8:30 a.m. ET (5:30 a.m.
PT) to review the financial results and answer questions. (.pdf)
February, 13, 2007, Somaxon Provides Update
on SILENOR Preclinical Program
- FDA agrees with the company’s assessment that doxepin
does not appear to have genotoxic potential
- Standard, long-term carcinogenicity studies may be a
Phase 4 commitment pending evaluation of all preclinical
data
- NDA timeline on track; third quarter 2007 submission
anticipated
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today is providing an update on its preclinical testing program for SILENOR™ (doxepin HCl), its lead product candidate that has completed a successful Phase 3 clinical
program for the treatment of insomnia. (.pdf)
February 12, 2007, Somaxon Pharmaceuticals to Update Preclinical Program
for SILENOR™ for the Treatment of Insomnia and Host Conference Call
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today said that, tomorrow morning, Tuesday, February 13, the company plans to
issue a news release, in which it will provide an update on the preclinical program for
SILENOR™ (doxepin HCl) for the treatment of insomnia. Additionally, Somaxon
management will host a conference call Tuesday morning at 9:00 a.m. Eastern Time to
review the preclinical program update. (.pdf)
January 29, 2007, SOMAXON PHARMACEUTICALS NAMES ROBERT JONES
VICE PRESIDENT, HUMAN RESOURCES
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today
announced the appointment of Robert Jones as Vice President, Human Resources, a newly created
position. (.pdf)
January 3, 2007, Somaxon Pharmaceuticals to Present at the JPMorgan Healthcare Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a
company update at the JPMorgan Healthcare Conference at The Westin St. Francis, San
Francisco, on Wednesday, January 10, 2007, at 10:30 a.m. Pacific Time (1:30 p.m. Eastern
Time). (.pdf)
